Choosing transcription factor and epigenetic antibodies: what a sox9 antibody, a jmjd3 antibody, a smyd3 antibody and the epigenetic antibodies sold beside them demand of a nuclear protocol, how a foxp3 antibody flow cytometry panel differs, and the controls a low abundance nuclear target needs

Working with a nuclear target

1. Use a permeabilisation that reaches the nucleus. The detergent and buffer that permeabilise a cytoplasmic protein frequently do not open the nuclear envelope adequately. Nuclear factor protocols use their own buffer systems, and for flow cytometry a dedicated nuclear permeabilisation kit is the practical answer rather than an adjustment.
2. Expect low abundance and plan the amplification. Many of these proteins are present at a small fraction of a structural protein's level, so a direct conjugate may simply not reach. Amplification through a biotinylated intermediate or a polymer detection system is what makes the signal visible, at the cost of harder quantitation.
3. Insist on a genetic negative, because isotype controls are weak here. An isotype control shows the format's background and says nothing about specificity for a nuclear protein at low abundance. A knockout, a knockdown or a cell type known not to express the factor is what separates signal from nuclear background.
4. Know whether the epitope is modification dependent. Several of these targets are read through their modifications, and an antibody against a modified residue will not see the unmodified protein and vice versa. Read the immunogen and ask for the specificity evidence, ideally a peptide array.
5. Match the reagent to the application, not the target. An antibody validated for chromatin immunoprecipitation has been shown to work on fixed, fragmented chromatin, which is a different demonstration from a western blot. Buy against the application you will run and read that application's evidence specifically.

Chromatin immunoprecipitation is a separate qualification

An antibody that detects a factor on a blot may not immunoprecipitate it from fixed, fragmented chromatin, where the epitope is cross-linked and partly buried. Ask for enrichment data at a known target locus and a known negative region.

Lot variation matters more here than almost anywhere else, because most such reagents are polyclonal and the mark or epitope is small. Buy the project's supply as one lot and record it.

Nuclear background and how to reduce it

Nuclei bind antibody non-specifically, and the usual remedies are longer blocking with a protein that is not related to the sample, a more dilute primary with a longer incubation, and a wash regime with detergent. All three help; a stronger antibody concentration does not.

Run the secondary-only control on nuclei specifically. A background that is present without the primary is a detection problem, and no amount of primary titration will fix it.

Reading a result about a factor that moves

Many transcription factors are regulated by translocation rather than by abundance, so a whole-cell measurement can be flat while the biology changes entirely. Fractionate, or image and measure a nuclear to cytoplasmic ratio per cell.

Where translocation is the readout, a per-cell ratio across a population is far more informative than a mean, because the response is frequently a change in the fraction of responding cells rather than a shift in all of them.

Common questions

Why can I not detect my transcription factor?

Usually abundance and permeabilisation. These proteins sit far below structural proteins in level and need a nuclear permeabilisation protocol; a cytoplasmic protocol reports absence rather than a low signal.

Is an isotype control enough for a nuclear stain?

No. It shows the background of the reagent format and nothing about specificity at low abundance in a nucleus full of protein. A genetic negative, or a cell type known not to express the factor, is what settles it.

What does a foxp3 antibody flow cytometry panel need that a surface panel does not?

A nuclear fixation and permeabilisation system, applied after the surface markers are stained, and surface markers that survive it. Several surface epitopes are damaged by nuclear permeabilisation buffers.

How do I judge an epigenetic antibody's specificity?

By evidence that it discriminates between neighbouring modification states, which means a peptide array or a dot blot against a panel of modified peptides, plus a peptide competition you can run yourself.

Browse by service class

• Compare Gene synthesis on advertised prices